A |
| Abciximab therapy,
for patients with unstable angina undergoing PTCA |
| Abdominal aortic aneurysm |
|
aortic grafts |
|
beta-blockade to
reduce rate of aortic dilatation |
|
screening |
| Air
pollution, effect of |
| Alcohol
consumption, and cardiovascular risk |
| Aminophylline, for
stroke |
| Amiodarone |
|
for myocardial
infarction |
| Angina, stable |
|
antiplatelet therapy |
|
|
in secondary prevention |
|
|
post-CABG |
|
|
post-PTCA and post-CABG |
|
coronary artery bypass grafting (CABG) |
|
|
in symptom relief |
|
|
versus PTCA |
|
drug
therapy |
|
ECG and exercise testing |
|
guidelines |
|
laser angioplasty,
rotational and directional coronary atherectomy |
|
lipid lowering
therapy |
|
Top
percutaneous transluminal coronary angioplasty (PTCA) |
|
|
calcium antagonists & fish oils following |
|
|
in symptom relief |
|
|
with elective stenting |
|
radionucleide imaging |
|
secondary
prevention |
|
smoking |
| Angina, unstable See Unstable angina |
| Angioplasty |
|
for carotid stenosis |
|
for peripheral vascular disease |
|
|
for intermittent claudication |
|
|
guidelines |
| Angiotensin converting enzyme (ACE) inhibitors |
|
for heart failure |
|
for myocardial
infarction |
| Ankle brachial
pressure index |
| Anticoagulation |
|
cardioversion for
atrial fibrillation following, in heart failure |
|
for
atrial fibrillation |
|
for heart failure |
|
for
stroke |
|
post-stenting in
stable angina |
|
vs aspirin for stroke |
Top
Antiplatelet therapy See also aspirin |
|
for acute myocardial
infarction |
|
for peripheral
vascular disease |
|
for previous
myocardial infarction |
|
for stable angina |
|
prophylactic, for
deep vein thrombosis |
|
vs clopidogrel for
myocardial infarction |
|
for stroke |
|
|
clopidogrel vs aspirin in secondary
prevention |
|
|
effect on outcomes |
|
|
in secondary prevention |
|
|
with aspirin in acute stroke |
|
for unstable angina |
|
in primary prevention |
|
|
for atrial fibrillation |
|
|
in low risk patients |
|
post-CABG |
|
|
reduction of MI, stroke or vascular death |
|
|
reduction of re-occlusion rates |
|
post-PTCR |
|
to prevent deep vein
thrombosis |
Top
Aortic aneurysm and peripheral vascular disease |
| Aortic grafts |
| Arrhythmias, See
also atrial fibrillation cardioverter
defibrillators and pacemakers |
| Aspirin See also Antiplatelet therapy |
|
and smoking cessation |
|
cost-effectiveness
with simvastatin and pravastatin for myocardial infarction |
|
for acute myocardial
infarction |
|
for non-rheumatic
atrial fibrillation |
|
for secondary
prevention of peripheral vascular disease |
|
for stable angina |
|
for stroke |
|
for unstable angina |
|
ticlopidine and
clopidogrel vs aspirin in myocardial infarction |
|
ticlopidine and
clopidogrel vs aspirin in secondary prevention of stroke and other outcomes |
|
with heparin for
myocardial infarction |
|
with heparin for
unstable angina |
|
with simvastatin for
myocardial infarction |
| Aspirin and heparin,
for unstable angina |
| Atrial fibrillation |
|
guidelines |
|
risk factor for
stroke |
Top
B |
| Beta-blockers |
|
for heart failure |
|
for myocardial
infarction |
| Bisoprolol |
|
for angina |
| Bystander
cardio-pulmonary resuscitation (CPR) |
C |
|
| Calcium supplements,
to reduce blood pressure |
| Cardiac rehabilitation |
|
exercise training for |
|
guidelines |
|
psychosocial
interventions |
|
smoking reduction |
| Cardiac
transplantation, for heart failure |
| Cardiomyoplasty, for
heart failure |
| Cardioversion, for
heart failure/atrial fibrillation, |
| Cardioverter
defibrillators, implantable |
| Carotid angioplasty |
| Carotid bruits, in
the diagnosis of carotid stenosis |
| Carotid endarterectomy |
|
carotid patching |
|
for adult patients
with carotid stenosis |
|
for severe carotid
stenosis |
|
guidelines |
|
routine shunting in |
| Carotid imaging, for
stroke |
| Carotid
stenosis |
| Carotid stents |
Top
Cholesterol |
|
effect of
psychosocial interventions |
|
for peripheral
vascular disease |
|
reduction,
in primary prevention |
|
reduction, in secondary
prevention |
|
relationship
with cardiovascular morbidity |
| Clinical guidelines. See Guidelines |
| Clopidogrel. See also antiplatelet therapy |
|
vs aspirin for
the secondary prevention of myocardial infarction |
|
vs aspirin for the secondary prevention of
peripheral vascular disease |
|
|
CAPRIE trial |
|
|
Cochrane review |
|
vs aspirin in
secondary prevention of stroke |
| Compression therapy, for venous leg ulcers |
|
4-layer bandaging |
|
importance of clinical
assessement to prevent inappropriate use |
|
in post-operative
prevention of deep vein thrombosis |
|
intermittent pneumatic
compression |
|
specialist vascular
assessment to determine most appropriate use |
| Congenital heart
disease |
|
echocardiograph |
|
extended mid-trimester
fetal echocardiography |
|
guidelines |
Top
Coronary artery bypass grafting (CABG) |
|
for heart failure |
|
for stable angina |
|
for unstable angina |
| Coronary atherectomy |
|
for angina |
| Coronary heart disease. See also Myocardial infarction |
|
guidelines for the |
|
|
management of atrial fibrillation |
|
|
prevention of coronary heart disease |
| Coronary
revascularisation, for unstable angina |
| Coronary stents |
| Corticosteroids, for
stroke |
| Cost effectiveness |
|
angiotensin converting
enzyme (ACE) inhibitors, in heart failure |
|
cardiac
catheterisation strategy, in unstable angina |
|
cardiac
rehabilitation |
|
coronary stents |
|
PTCA or CABG vs
medical therapy, in stable angina |
|
PTCA vs CABG, in
stable angina |
|
simvastatin and
prevastatin, in secondary prevention |
|
statins, in primary
prevention |
| CT brain scanning. See Diagnostic imaging |
Top
D |
| D-dimer testing, in
the diagnosis of deep vein thrombosis |
| Deep vein
thrombosis |
|
drug
therapy |
|
guidelines for the
prophylaxis of venous thromboembolism |
|
secondary prevention |
| Defibrillation, basic
and advanced life support, for myocardial infarction |
| Diabetes, as
risk factor for cardiovascular disease |
| Diagnostic imaging |
|
for angina |
|
for
congenital heart disease |
|
for
deep vein thrombosis |
|
for
heart failure |
|
for leg ulcer |
|
for
stroke |
|
|
carotid imaging |
| Digoxin, for heart
failure |
| Dipyridamole,
synergistic effect of aspirin with in stroke |
| Diuretics, for heart
failure |
| Dysphagia, after
stroke |
E |
Top |
| Echocardiography |
|
extended mid-trimester
fetal, for congenital heart disease |
|
for assessement of
heart disease |
|
guidelines |
|
in the evaluation of
heart failure |
| Electrical stimulation |
|
for leg ulcers |
| Electrocardiograph (ECG) and exercise
testing |
| Exercise, |
|
for intermittent
claudication |
|
to
reduce cardiovascular risk |
| Exercise training, for
cardiac rehabilitation |
| Extracranial-intracranial
arterial anastomosis (EC/IC bypass) |
F |
| Femoro-popliteal
bypass surgery |
| Fibrinogen depleting
agents, for stroke |
Top
G |
| Glycerol treatment,
for stroke |
| Glycoprotein IIb/IIIa inhibitors |
|
in addition to
aspirin and ticlopidine in stenting for stable angina |
|
trials of in
treatment of unstable angina |
| Guidelines |
|
angina |
|
atrial fibrillation,
management |
|
cardiac
rehabilitation |
|
cardiac pacemakers
and implantable cardioverter defibrillators |
|
chronic leg ulcer |
|
congenital
heart disease |
|
coronary heart
disease |
|
dysphagia mangement,
after stroke |
|
echocardiography |
|
exercise testing |
|
heart
failure |
|
hypertension,
management |
|
myocardial infarction |
|
myocardial
infarction, pre-hospital management |
|
peripheral vascular
disease, drug therapy |
|
prophylaxis of
venous thromboembolism |
|
radionucleide
myocardial perfusion imaging |
|
rehabilitation, after
stroke |
|
unstable angina |
|
valvular heart
disease |
| H |
Top |
| Haemodilution |
|
for peripheral
vascular disease |
|
for stroke |
| Heart failure |
|
cardiac
transplantation |
|
cardiomyoplasty |
|
coronary artery bypass
grafting |
|
drug
therapy |
|
echocardiography |
|
guidelines |
|
immunisation,
influenza and pneumococcal |
|
surgical
management |
| Heparin. |
|
[See also antiplatelet therapy, |
|
anticoagulant
therapy, |
|
low molecular weight heparins] |
|
for myocardial
infarction |
|
for primary
prevention of deep vein thrombosis |
|
for secondary
prevention of deep vein thrombosis |
|
for treatment of
deep vein thrombosis |
|
for venous
thromboembolism |
|
for unstable angina |
|
|
during acute phase |
|
|
with long-term aspirin |
|
risk of
thrombocytopenia |
| Heparin and aspirin, for unstable angina |
|
during acute phase |
|
in long-term |
| Hirudin vs heparin
for myocardial infarction |
| Hypertension |
|
as risk
factor for stroke and coronary heart disease |
|
guidelines |
|
in diabetes |
Top
I |
| Ibopamine, for heart
failure |
| Iloprost, for
peripheral vascular disease |
| Immunisation,
influenza and pneumococcal, for patients with heart failure |
| Implantable
cardioverter defibrillator |
| Intermittent claudication |
|
angioplasty |
|
exercise for |
| Intracerebral
haematoma |
L |
| Laser angioplasty, for
angina |
| Laser therapy, for
leg ulcers |
| Leg ulcers |
|
clinical
assessment |
|
compression
therapy |
|
diagnostic imaging |
|
dressings |
|
drug therapy |
|
|
oral zinc sulphate |
|
|
stanozolol or rutoside |
|
guidelines |
|
laser therapy and
electrical stimulation |
|
leg ulcer clinics |
|
topical analgesics,
topical anaesthetics and dressings |
|
ultrasound to enhance
healing |
| Lipid-lowering therapy, See cholesterol |
| Losartan, for heart
failure |
| Lovastatin, for
secondary prevention |
| Low
molecular weight heparins See also Heparins |
|
in prevention of
deep vein thrombosis |
|
in stroke |
|
|
in acute phase |
|
|
vs aspirin |
|
in treatment of
deep vein thrombosis |
|
in unstable angina |
M |
Top |
| Magnesium sulphate,
in myocardial infarction |
| Magnetic resonance imaging (MRI). See Diagnostic imaging |
| Mannitol, for stroke |
| Mononitrate therapy |
|
for myocardial
infarction |
| MRI scanning. See Diagnostic imaging |
| Myocardial infarction |
|
bystander
cardio-pulmonary resuscitation |
|
cardiac rehabilitation |
|
drug therapy |
|
guidelines for
management |
|
guidelines for
pre-hospital management |
|
guidelines for the
prevention of coronary heart disease |
|
out-of-hospital
defibrillation, basic and advanced life support |
|
patient education |
|
percutaneous
transluminal coronary angioplasty (PTCA) for |
|
secondary prevention |
|
thrombolytic therapy |
| Myocardial perfusion imaging, See Diagnostic imaging |
N |
Top |
| Nifedipine |
|
for myocardial
infarction |
| Nimodipine, for
stroke |
| O |
|
| Obesity |
|
as risk factor
for angina, myocardial infarction or stroke |
|
as risk factor for leg
ulceration |
P |
Top |
| Pacemakers |
| Patient education, for
patients with coronary heart disease |
| Pentoxifylline |
|
for peripheral vascular disease |
|
|
Cochrane review |
|
|
vs exercise |
|
for stroke |
| Percutaneous transluminal coronary angioplasty
(PTCA) |
|
and abciximal in
unstable angina |
|
and smoking risk |
|
antiplatelet therapy following |
|
|
in reduction of myocardial infarction,
stroke or vascular death |
|
|
in reduction of re-occlusion rates |
|
calcium antagonists
and fish oils, following |
|
with elective
stenting,for angina |
|
immediate,for
myocardial infarction |
Top
Peripheral vascular
disease |
|
drug
therapy |
|
drug therapy,
guidelines |
|
lipid-lowering
therapy |
|
secondary prevention |
|
smoking cessation |
|
surgical
management |
| Phosphodiesterase
inhibitors, for heart failure |
| Physical activity, See Exercise |
| Potassium
supplements, to reduce blood pressure |
| Pravastatin |
|
for primary prevention |
|
for secondary prevention |
|
|
cost-effectiveness |
|
|
risk reduction |
| Prevention of
cardiovascular disease |
|
air
pollution |
|
alcohol
consumption |
|
anticoagulation
for atrial fibrillation |
|
antiplatelet
therapy |
|
cholesterol |
|
glycaemic
control in diabetes |
|
guidelines for prevention of
coronary heart disease |
|
hypertension |
|
obesity |
|
oral potassium
supplements |
|
physical
activity |
|
smoking, active
and passive |
|
sodium intake |
|
treatment of
hypertension in diabetes |
|
weight loss |
| Propentofylline, for
stroke |
| Prostacyclin, for
stroke |
| Psychosocial interventions |
|
within cardiac
rehabilitation schemes |
R |
Top |
| Radionucleide imaging, See Diagnostic imaging |
| Rutoside, for leg
ulcers |
S |
|
| Simvastatin, for secondary prevention |
|
cost-effectiveness |
|
risk reduction |
| Smoking |
|
and pravastatin
therapy for cholesterol reduction |
|
and pravastatin
therapy for myocardial infarction |
|
and risk of coronary
heart or peripheral vascular disease |
|
and risk of death
following PTCA |
|
cessation as
protective effect compared to exercise |
|
cost-effectiveness of
statins with smoking cessation in primary prevention |
|
cost-effectiveness of
statins with smoking cessation in secondary prevention |
|
effect of cessation
on intermittent claudication |
|
effect on cessation
of multifactorial cardiac rehabilitation |
|
passive |
| Sodium intake, and
hypertension |
| Stanozolol, for leg
ulcers |
| Statins |
|
for the primary prevention of myocardial infarction
|
|
|
lovastatin |
|
|
pravastatin |
|
for the secondary prevention of myocardial
infarction |
|
|
cost-effectiveness of statins |
|
|
pravastatin |
|
|
simvastatin |
| Stents, coronary |
Top
Stroke |
|
carotid
stenosis |
|
diagnostic
imaging |
|
drug
therapy |
|
dysphagia, guidelines |
|
multidisciplinary
assessment |
|
rehabilitation,
guidelines |
|
remedial therapy |
|
secondary
prevention |
|
stroke unit care |
|
surgical management |
|
thrombolytic therapy |
|
venous
thromboembolism, prevention |
T |
|
| Theophylline, for
stroke |
| Therapy services, for
stroke |
| Thrombocytopenia |
| Thromboembolism,
venous, prevention in stroke |
| Thrombolytic therapy |
|
for myocardial
infarction |
|
for stroke |
|
for unstable angina |
| Thrombophilia |
| Ticlopidine |
|
and clopidogrel vs
aspirin for secondary prevention of myocardial infarction |
|
and clopidogrel vs
aspirin for secondary prevention of peripheral vascular disease |
|
and clopidogrel vs
aspirin for secondary prevention of stroke |
U |
Top |
| Ultrasonography |
|
in the diagnosis of
deep vein thrombosis |
|
vs angiography in
assessment of carotid stenosis |
| Unstable angina |
|
antiplatelet and
anticoagulant therapy |
|
coronary
revascularisation |
|
early invasive vs
early conservative strategies |
|
guidelines |
|
thrombolytic therapy |
V |
|
| Valvular heart disease |
|
management guidelines |
| Varicose veins and leg
ulcers clinical assessment |
|
compression
therapy |
|
guidelines |
|
surgical
management |
| Vasoactive drugs, for
stroke |
W |
|
| Warfarin |
|
comparison with
aspirin in prevention of stroke |
| Weight loss |
Z |
|
Zinc sulphate, oral
for leg ulcers
-
|
